Prognosis of patients with ischemia, nonobstructive CAD can change over time
Click Here to Manage Email Alerts
In the CIAO ancillary study of patients who were screened for the ISCHEMIA trials but were excluded because they had ischemia but no obstructive CAD, stress echocardiography results and angina frequency changed over time, researchers reported at the virtual American College of Cardiology Scientific Session.
In addition, there was no correlation between change in ischemia and change in angina at 1 year in patients with ischemia but no obstructive CAD (INOCA) on coronary CT angiography, Harmony R. Reynolds, MD, associate professor of medicine and associate director of the Cardiovascular Clinical Research Center at NYU Langone Health, said during a presentation.
The researchers compared 208 patients with INOCA with 865 patients with obstructive CAD who were enrolled in ISCHEMIA. They also conducted longitudinal assessments of the patients with INOCA enrolled in CIAO between baseline and 1 year. The primary outcome was the correlation between change in ischemia and change in angina; 187 patients from the CIAO cohort were available for that analysis.
Changes over 1 year
“Persistent symptoms are a marker of risk among INOCA patients. A positive stress test, such as a stress echocardiogram, is also a marker of risk,” Reynolds said during the presentation. “However, whether myocardial ischemia is solely responsible for angina in INOCA patients is uncertain. Expert recommendations focus on symptom management, and our aim was to investigate changes in symptoms and stress testing in INOCA patients over 1 year, leveraging the enrollment process of the international, NHLBI-funded ISCHEMIA trial.”
The INOCA cohort had a much greater proportion of women than the obstructive CAD cohort (66% vs. 26%; P < .001), Reynolds said. In addition, compared with the obstructive CAD cohort, the INOCA cohort was younger (63 years vs. 66 years; P = .004), less likely to have diabetes (19% vs. 33%; P < .001), less likely to have prior MI (2% vs. 15%; P < .001), less likely to be a current or former smoker (41% vs. 56%; P = .001) and more likely to have depression (19% vs. 9%; P < .001).
Among the INOCA cohort, 71% were indicated for stress testing because of typical angina and/or atypical chess pain, and 49% were indicated because of shortness of breath, she said.
Both groups had a median of four ischemic segments on stress echocardiography, but the difference was significant (P = .03) because more patients from the obstructive CAD cohort had very severe ischemia, Reynolds said. In addition, the INOCA cohort was less likely to have anterior ischemia (44% vs. 58%; P < .001).
At enrollment, the Seattle Angina Questionnaire-7 score was higher in the INOCA cohort than the obstructive CAD cohort (83 vs. 78; P = .036) and the SAQ Angina Frequency score was lower in the INOCA cohort (90 vs. 100; P < .001), according to the researchers.
There was no correlation at enrollment between angina frequency and ischemia severity in the INOCA cohort (P = .462) and the obstructive CAD cohort (P = .353), Reynolds said.
In blinded core laboratory readings of change in ischemia segments in the INOCA cohort, “50% of studies normalized at 1 year and 45% of the studies were unchanged or worse,” she said.
At 1 year, the INOCA cohort improved in SAQ-7 score and SAQ Angina Frequency score (P < .001 for both), with 39% improving at least 10 points in angina frequency score and 52% improving at least 5 points in SAQ-7 score, she said, noting that the median number of anti-anginal medications was 1 at both enrollment and 1 year.
There was no correlation between 1-year change in ischemia severity and 1-year change in either angina score, which held true in all subgroup analyses, Reynolds said.
There was a correlation between symptoms at enrollment and symptoms at 1 year (r based on angina frequency score = 0.49; r based on SAQ-7 score = 0.58; P < .001 for both), she said.
Secondary event prevention
During a discussion of the trial, Cardiology Today Editorial Board Member C. Noel Bairey Merz, MD, FACC, FAHA, FESC, professor of medicine and director of the Barbra Streisand Women's Heart Center, the Preventive and Rehabilitative Cardiac Center, the Cedars-Sinai Clinical Scholars Program and the Linda Joy Pollin Women's Heart Health Program at Cedars-Sinai said “as many as half of INOCA patients don’t have frequent angina and have pretty preserved quality of life, and therefore symptom management may not be an issue for them. We know from other work that an abnormal stress test in the face of open arteries does have an adverse prognosis. We also know that CORMICA demonstrated you can improve symptoms in these patients with endotyping, and the SCOT-HEART trial of CT angiography portended an adverse prognosis if there was coronary atherosclerosis and secondary prevention was not deployed.
“So, we can learn from CIAO-ISCHEMIA that CT angiographies are potentially going to be helpful to risk-stratify these patients, and do a better job for prevention of secondary events, not necessarily symptom management,” she said.
If identified correctly, these patients could be treated with calcium channel blockers, but “if coronary atherosclerosis is evident, we are also testing if medications from secondary prevention guidelines such as high-intensity statins, ACE inhibitors or angiotensin receptor blockers and aspirin should be deployed in these patients,” she said.
Of note, she added, patients with INOCA whose symptoms did not resolve “probably have coronary microvascular dysfunction, which is a persistent and chronic problem which erodes quality of life. Adverse prognosis dictated by coronary flow reserve abnormalities is important and should be attended to. These trials endorse further probe trials of pharmacological therapies for flow reserve, as well as large MACE trials because of this adverse prognosis.” – by Erik Swain
Reference:
Reynolds HR, et al. Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials. Presented at: American College of Cardiology Scientific Session; March 28-30, 2020 (virtual meeting).
Disclosures: Reynolds reports she has financial ties with Abbott, Medscape and Merck. Bairey Merz reports no relevant financial disclosures.